BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Patrys Limited (PATZF.PK) Anti-Cancer Product Shows Promise in Multiple Myeloma


8/17/2011 7:18:07 AM

Melbourne, Australia; 17 August, 2011: Patrys Limited (ASX: PAB; “the Company”), today announced the results of preclinical work conducted at The University Hospital of Würzburg showing the activity of one of Patrys’ products in multiple myeloma.

Multiple myeloma is a type of bone marrow cancer arising from plasma cells, which are normally found in the bone marrow. Plasma cells form part of the body’s immune system.

According to Dr Leo Rasche, the study’s lead investigator at the Department of Hematology and Oncology, the University Hospital of Würzburg, “a major obstacle in the successful treatment of multiple myeloma is disease recurrence due in part to the outgrowth of chemotherapy- and novel agents-resistant plasma cells.”

“This study shows that Patrys’ product can specifically bind to multiple myeloma cells from both patients at the stage of primary diagnosis and also in relapsed individuals. In addition, Patrys’ product mediates cell death in primary cells isolated patients and typical cell lines used to study the disease in vitro. We believe these encouraging data provide sufficient proof of concept to warrant further study in multiple myeloma patients.”

“The studies conducted offer promise in the multiple myeloma space where there are few treatments available, except for chemotherapeutics. The potential for Patrys’ product to be used in relapsed patients is particularly exciting,” added Dr Marie Roskrow, Patrys’ Chief Executive Officer.

Of the approximately 1,200 Australians who are diagnosed with multiple myeloma each year, almost all are older than 40 years. Multiple myeloma is most common in people aged 60 years and older, and men are affected more often than women. In the United States, an estimated 20,520 adults will be diagnosed with multiple myeloma. It is estimated that 10,610 deaths from this disease will occur this year.

The five-year survival rate (percentage of people who survive at least five years after the cancer is detected, excluding those who die from other diseases) of people with multiple myeloma is about 39%. However, several factors affect an individual’s survival, such as the person’s age and overall health.

“This study exemplifies the importance of our ongoing collaboration with Dr. Rasche and his associates at the University Hospital of Würzburg as well as our continuing commitment to enhancing our pipeline of novel antibody candidates. Our robust research capabilities continue to generate a pipeline of technologies that we are developing into viable commercial treatments,” said Dr Marie Roskrow.

This work is supported by an IZKF grant awarded in 2010 to Dr Leo Rasche.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES